Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome 
Methods
Using simulations, we quantified the bias in the treatment effect estimator in TAMS trials for different designs. We also retrospectively`re-designed' completed cancer trials as TAMS trials and used the bootstrap to quantify bias.
Results
In trials in which the experimental treatment is better than the control and which continue to their planned end, the bias in the estimate of treatment effect is small and of no practical importance. In trials stopped for lack of benefit at an interim stage, the treatment effect estimate is biased at the time of interim assessment. This bias is markedly reduced by further patient follow-up and reanalysis at the planned`end' of the trial.
Conclusions
Provided that all patients in a TAMS trial are followed up to the planned end of the trial, the bias in the estimated treatment effect is of no practical importance. Bias correction is then unnecessary.
